Lenalidomide G.L. (Lenalidomide)

Lenalidomide binds to the cereblon component of the E3 ubiquitin ligase complex, leading to targeted degradation of transcription factors essential for malignant cell survival. This action enhances immune‑mediated tumor cell killing, inhibits new blood‑vessel formation, and directly triggers apoptosis of cancerous plasma cells.

The dosage of Lenalidomide is individualized and determined by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. Patients should follow the exact dosing schedule provided by their healthcare professional and not adjust the dose on their own.

Lenalidomide is contraindicated during pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception before, during, and after treatment. The safety of Lenalidomide during breastfeeding has not been established, and nursing is generally not recommended while on therapy.

To place an order, submit an enquiry on the Lenalidomide G.L. product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both Lenalidomide and thalidomide belong to the immunomodulatory drug class, but Lenalidomide is generally more potent, has a more favorable safety profile, and is associated with lower rates of peripheral neuropathy. Lenalidomide also offers stronger anti‑angiogenic activity and is approved for a broader range of hematologic indications.

Lenalidomide tablets should be stored at temperatures below 25 °C (77 °F) in their original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity, which could affect its stability.

Lenalidomide is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a full glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or anemia that can predispose to infection, opportunistic infections, second primary malignancies, and significant liver toxicity. Patients should be monitored closely for signs of these complications and report any concerning symptoms promptly.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to the drug, or patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment, uncontrolled cardiovascular disease, or a history of thromboembolic events unless appropriate prophylaxis is in place.